Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
Ewan R. Pearson, Stefano Del Prato, Imre J. Pavo, Denise Reis Franco et autres
This post hoc analysis assessed sustainability of lowered HbA1c and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. Participants achieving HbA1c ≤48 mmol/mol (6.5%) or weight loss ≥10% at 52 weeks were evaluated for sustained glycemic or …
Ewan R. Pearson, Stefano Del Prato, Imre J. Pavo, Denise Reis Franco et autres
This post hoc analysis assessed sustainability of lowered HbA1c and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. Participants achieving HbA1c ≤48 mmol/mol (6.5%) or weight loss ≥10% at 52 weeks were evaluated for sustained glycemic or …
Ewan R. Pearson, Stefano Del Prato, Imre J. Pavo, Denise Reis Franco et autres
This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. Participants achieving HbA1c ≤48 mmol/mol (6.5%) or weight loss ≥10% at 52 weeks were evaluated for sustained …
gb, it, us, br (code pays fourni par la source)
Philip Scott Zeitler, Rodolfo Javier Galindo, Melanie J. Davies, Brandon K. Bergman et autres
OBJECTIVE: We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS: This post hoc analysis compared baseline characteristics and changes …
us, gb (code pays fourni par la source)
Philip Scott Zeitler, Rodolfo Javier Galindo, Melanie J. Davies, Brandon K. Bergman et autres
Objective: We evaluated baseline characteristics of participants with early-onset T2D from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. Research Design and Methods: This post hoc analysis compared baseline characteristics and changes in mean HbA1c, …
Philip Scott Zeitler, Rodolfo Javier Galindo, Melanie J. Davies, Brandon K. Bergman et autres
Objective: We evaluated baseline characteristics of participants with early-onset T2D from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. Research Design and Methods: This post hoc analysis compared baseline characteristics and changes in mean HbA1c, …
Rodolfo Javier Galindo, Philip Scott Zeitler, Melanie J. Davies, Clare J. Lee et autres
How do baseline characteristics in the SURPASS Program differ between individuals with young-onset vs later-onset type 2 diabetes (T2D)? Methods : In this post-hoc analysis, baseline demographics and clinical characteristics were compared in participants with young-onset vs later-onset T2D from the SURPASS-1, …
us, gb (code pays fourni par la source)
Philip Scott Zeitler, Rodolfo Javier Galindo, Melanie J. Davies, Brandon K. Bergman et autres
Does treatment with tirzepatide (TZP) improve glycemic control, body weight (BW) and cardiometabolic markers in participants with early-onset T2D? Method : In this post-hoc analysis changes from baseline in mean HbA1c, BW, waist circumference (WC), and cardiometabolic markers including lipids, and blood …
us, gb (code pays fourni par la source)
Francesco Giorgino, Denise Reis Franco, Claudia Nicolay, Andrea Hemmingway et autres
OBJECTIVE: This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based …
it, us (code pays fourni par la source)
Francesco Giorgino, Denise Reis Franco, Claudia Nicolay, Andrea Hemmingway et autres
Objective This post hoc analysis assessed change from baseline to Week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3) and glargine (SURPASS-4) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting …
Francesco Giorgino, Denise Reis Franco, Claudia Nicolay, Andrea Hemmingway et autres
Objective This post hoc analysis assessed change from baseline to Week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3) and glargine (SURPASS-4) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting …
Andrew Anand Brown, Juan J. Fernandez-Tajes, Mun‐Gwan Hong, Caroline Brorsson et autres
We evaluate the shared genetic regulation of mRNA molecules, proteins and metabolites derived from whole blood from 3029 human donors. We find abundant allelic heterogeneity, where multiple variants regulate a particular molecular phenotype, and pleiotropy, where a single variant associates with multiple …
gb, se, dk, ch, de, fr, fi, nl, it, us, es (code pays fourni par la source)
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.
L'essentiel de l'actu tech du Burkina & d'Afrique, chaque semaine dans votre boîte mail.
Gratuit · sans spam · désinscription en un clic